Lenalidomide exerts pharmacological action through the ubiquitin‐dependent degradation of IKZF1 and subsequent down‐regulation of IRF4, a critical factor for the survival of MM cells.6, 7, 8. The gene discussed is IRF4; the disease is Miyoshi myopathy.